RT Journal Article
SR Electronic
T1 Management of Nail Disease in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations
JF The Journal of Rheumatology
JO J Rheumatol
FD The Journal of Rheumatology
SP 433
OP 437
DO 10.3899/jrheum.220313
VO 50
IS 3
A1 Dhruvkumar Laheru
A1 Anna Antony
A1 Sueli Carneiro
A1 Vito Di Lernia
A1 Amit Garg
A1 Thorvardur Jon Love
A1 Karla del Rocio Macias Garcia
A1 José Alexandre Mendonça
A1 Sandeep Mukherjee
A1 Rodica Olteanu
A1 Lourdes Perez-Chada
A1 Cheryl F. Rosen
A1 Rachel Tannenbaum
A1 Michel Alexandre Yazbek
YR 2023
UL http://www.jrheum.org/content/50/3/433.abstract
AB Objective Nail psoriasis is common, impairs fine motor finger functioning, affects cosmesis, and is associated with a lower quality of life. This review updates the previous Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) treatment recommendations for nail psoriasis.Methods This systematic literature review of the PubMed, MEDLINE, Embase, and Cochrane databases examined the updated evidence since the last GRAPPA nail psoriasis treatment recommendations published in 2014. Recommendations are based on preformed PICO (Patient/Population - Intervention - Comparison/Comparator - Outcome) questions formulated by an international group of dermatologists, rheumatologists, and patient panel members. Data from this literature review were evaluated in line with Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology.Results Overall, there is insufficient evidence to make any recommendation for the use of topical corticosteroids, topical calcipotriol, topical tazarotene, topical cyclosporine, dimethyl fumarates/fumaric acid esters, phototherapy, and alitretinoin. There is a low strength of evidence to support the use of calcipotriol and corticosteroid preparations, topical tacrolimus, oral cyclosporine, oral methotrexate, intralesional corticosteroids, pulsed dye laser, acitretin, Janus kinase inhibitors, and apremilast.Conclusion The highest strength of supporting evidence is for the recommendation of biologic agents including tumor necrosis factor inhibitors, and interleukin 12/23, 17, and 23 inhibitors.